Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Studies how physical activity relates to inflammation in Parkinson's disease

Observes how regular exercise may affect inflammation in people with Parkinson's disease.

Key facts

Who runs it
IRCCS National Neurological Institute "C. Mondino" Foundation
Where
Pavia, ItalySee the site
Trial code
Registry title
Physical Activity on Neuroinflammation in Parkinson's Disease
Status
Recruiting
People taking part
40 people, planned
Started
1 Jan 2023
Planned end
1 Jun 2026
Type of study
Observational, 2 groups
Record updated
18 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with Parkinson's disease, some who exercise intensely and regularly and some who lead a sedentary life. It compares signs of inflammation in the body.

Age
40 to 80 years (both included)
Sex
Women and men can both join.
Disease stage
Parkinson's disease diagnosed by Movement Disorder Society criteria, Hoehn & Yahr stage 1 to 3.
Earlier treatment
People with a deep brain stimulation implant or on DuoDopa therapy cannot join. People on N-acetylcysteine or anti-oxidants cannot join.

Main reasons for not taking part

  • Other neurological diseases at the same time
  • Confirmed cognitive decline (MMSE < 24) or depression (BDI > 40)
  • Body Mass Index (BMI) >= 30 or active smoking
  • Acute or recent infections
  • Pregnancy or lactation

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Subjects of both sexes, aged between 40 and 80 years (extremes included)
  • Diagnosis of Parkinson's disease according to the clinical diagnostic criteria of the Movement Disorder Society
  • Hoehn \& Yahr between 1 and 3

Who cannot take part

  • Concomitant diagnosis of other neurological diseases
  • Patients with deep brain stimulation implant or undergoing DuoDopa therapy
  • Ongoing treatment with N-acetylcysteine or anti-oxidants
  • Presence of significant diseases affecting the musculoskeletal system
  • Presence of internal medicine conditions, considered clinically significant by the investigator
  • Acute or recent infections
  • Presence of confirmed cognitive decline (MMSE < 24)
  • Presence of depression with (BDI > 40)
  • Body Mass Index (BMI) >= 30
  • Active smoking behavior
  • Pregnancy or lactation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 80 years old?

Where in Italy

  • IRCCS Mondino FoundationPavia, ItalyContact: Roberto De IccoTaking people

About the trial

What the trial wants to find out

Parkinson's Disease (PD) is a chronic progressive neurodegenerative disorder clinically defined by the association of resting tremor, rigidity, bradykinesia, and postural instability. The histopathology of PD is characterized by the loss of neurons in the substantia nigra pars compacta (SNPc) and the accumulation of α-synuclein aggregates within Lewy bodies. The pathogenic mechanisms underlying the development of the disease, however, are not yet fully understood: genetics, cellular oxidative stress, mitochondrial dysfunction, environmental factors, and neuroinflammation are all potential mechanisms involved in the pathogenesis of PD.

Read full original descriptionShow less

Several studies have now established the involvement of neuroinflammation in the pathogenesis of PD. It is known that α-synuclein aggregates stimulate microglia and astroglia to secrete pro-inflammatory mediators such as IL 1β, IL6, and TNFα. These molecules activate an inflammatory response characterized by altered blood-brain barrier permeability, leukocyte recruitment, and the expression of other pro-inflammatory cytokines. These events contribute to exposing neurons to oxidative stress and cellular damage. Additionally, cellular damage induces neurons to stimulate the release of DAMPs (Damage Associated Molecular Patterns), which in turn activate glial cells. This creates a state of chronic inflammation that could play a role in the progression of the disease. Supporting this hypothesis, elevated levels of IL1β, IL6, and TNFα have been found in the striatum and SNPc of post-mortem PD samples.

The transcription factor Nrf2 is one of the main regulators of cellular protection in response to stress (inflammation, redox, xenobiotics). Nrf2 promotes the expression of several genes that cooperate in a cytoprotective response, which includes antioxidant defense, resolution of inflammation, increased mitochondrial activity, and protein turnover. Recent clinical studies seem to confirm the hypothesis that Nrf2 plays a role in the pathogenesis of PD, as already suggested by preclinical models. Specifically, altered plasma levels of the Nrf2-activated pathway have been observed in preclinical models.

Studies conducted on animal models of PD have hypothesized how exercise might correlate with protective mechanisms and might promote neuroplasticity and neuro-regeneration, especially when practiced at high intensity. Physical exercise can indeed modulate various systems (including inflammatory pathways and oxidative stress) that regulate neuroinflammation and glial activation. However, the available results are not definitive and often focus on single and separate aspects of the disease.

The aim of the study is to investigate the beneficial effect of physical exercise in patients with Parkinson's Disease (PD). Literature already suggests an improvement in various domains of motor and non-motor aspects, as well as in the overall quality of life, of PD patients even after a period of aerobic activity. Generally, training periods included 3-4 sessions per week of 40-60 minutes each for 4-16 weeks. In general, the literature describes the effects of moderate physical training, while little or nothing is known about how PD is affected by high-intensity sports training.

The primary objective of our study is to compare a group of PD patients undergoing regular and constant intense exercise (PD-sport) with a control group consisting of PD patients leading a sedentary life (PD-sedentary). The primary outcome will be the difference in systemic inflammatory status between the PD-sport group and the PD-sedentary group.

The 2 groups in the trial

  • PD-SPORT

    In PD-SPORT group the investigators aim to enroll subjects affected by Parkinson's Disease who regularly performed intensive physical activity. For the purpose of this study, the intensive physical activity is defined by the International Physical Activity questionnaire (IPAQ).

  • PD-SEDENTARY

    In PD-SEDENTARY group the investigators aim to enroll subjects affected by Parkinson's Disease who did not regularly performed intensive physical activity. For the purpose of this study, the intensive of physical activity is defined by the International Physical Activity questionnaire (IPAQ).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Role of Physical Activity on Neuroinflammation in Parkinson's Disease
Plain-language title
Studies how physical activity relates to inflammation in Parkinson's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06977204, who can take part
Record updated
18 May 2025